

Mario Strazzabosco

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3351139/publications.pdf>

Version: 2024-02-01

146
papers

9,475
citations

34076

52
h-index

43868

91
g-index

164
all docs

164
docs citations

164
times ranked

9864
citing authors

#	ARTICLE	IF	CITATIONS
1	The Neglected Role of Bile Duct Epithelial Cells in NASH. <i>Seminars in Liver Disease</i> , 2022, 42, 034-047.	1.8	8
2	Adjusting Barcelona Clinic Liver Cancer Staging System to the Evolving Landscape of Hepatocellular Carcinoma: A Look to the Future. <i>Gastroenterology</i> , 2022, 162, 2106-2108.	0.6	3
3	Inflammatory pathways and cholangiocarcinoma risk mechanisms and prevention. <i>Advances in Cancer Research</i> , 2022, , .	1.9	2
4	Diabetes medications and risk of HCC. <i>Hepatology</i> , 2022, 76, 1880-1897.	3.6	39
5	Bile acids and their receptors: modulators and therapeutic targets in liver inflammation. <i>Seminars in Immunopathology</i> , 2022, 44, 547-564.	2.8	39
6	Optimization of the BCLC Staging System for Locoregional Therapy for Hepatocellular Carcinoma by Using Quantitative Tumor Burden Imaging Biomarkers at MRI. <i>Radiology</i> , 2022, 304, 228-237.	3.6	17
7	Dysregulation of the Scribble/YAP/Î²-catenin axis sustains the fibroinflammatory response in a PKHD1 ^{âˆ’/âˆ’} mouse model of congenital hepatic fibrosis. <i>FASEB Journal</i> , 2022, 36, e22364.	0.2	2
8	Translational Value of Tumor-Associated Lymphangiogenesis in Cholangiocarcinoma. <i>Journal of Personalized Medicine</i> , 2022, 12, 1086.	1.1	5
9	The Tumor Microenvironment in Cholangiocarcinoma Progression. <i>Hepatology</i> , 2021, 73, 75-85.	3.6	100
10	IL-17A/F enable cholangiocytes to restrict T cell-driven experimental cholangitis by upregulating PD-L1 expression. <i>Journal of Hepatology</i> , 2021, 74, 919-930.	1.8	18
11	Intrahepatic cholangiocarcinoma: Morpho-molecular pathology, tumor reactive microenvironment, and malignant progression. <i>Advances in Cancer Research</i> , 2021, 149, 321-387.	1.9	18
12	Reliable prediction of survival in advanced-stage hepatocellular carcinoma treated with sorafenib: comparing 1D and 3D quantitative tumor response criteria on MRI. <i>European Radiology</i> , 2021, 31, 2737-2746.	2.3	8
13	Targeted therapies for extrahepatic cholangiocarcinoma: preclinical and clinical development and prospects for the clinic. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 377-388.	1.9	5
14	Rare and undiagnosed liver diseases: challenges and opportunities. <i>Translational Gastroenterology and Hepatology</i> , 2021, 6, 18-18.	1.5	1
15	Fibrocystic liver disease: novel concepts and translational perspectives. <i>Translational Gastroenterology and Hepatology</i> , 2021, 6, 26-26.	1.5	21
16	New insights on the role of vascular endothelial growth factor in biliary pathophysiology. <i>JHEP Reports</i> , 2021, 3, 100251.	2.6	28
17	Pathological characteristics of liver sinusoidal thrombosis in COVIDâ€™19 patients: A series of 43 cases. <i>Hepatology Research</i> , 2021, 51, 1000-1006.	1.8	24
18	Thermal ablation alone vs thermal ablation combined with transarterial chemoembolization for patients with small (<3Âˆcm) hepatocellular carcinoma. <i>Clinical Imaging</i> , 2021, 76, 123-129.	0.8	4

#	ARTICLE	IF	CITATIONS
19	Liver injury in COVID-19 and IL-6 trans-signaling-induced endotheliopathy. <i>Journal of Hepatology</i> , 2021, 75, 647-658.	1.8	67
20	Congenital Cystic Lesions of the Biliary Tree. , 2021, , 19-46.		0
21	Improved performance and consistency of deep learning 3D liver segmentation with heterogeneous cancer stages in magnetic resonance imaging. <i>PLoS ONE</i> , 2021, 16, e0260630.	1.1	5
22	Clinical outcome indicators in chronic hepatitis B and C: A primer for value-based medicine in hepatology. <i>Liver International</i> , 2020, 40, 60-73.	1.9	5
23	Value-based medicine, a compass to guide healthcare decisions in the COVID-19 aftermath. <i>Liver International</i> , 2020, 40, 2076-2078.	1.9	0
24	Abnormal Liver Function Tests in Patients With COVID-19: Relevance and Potential Pathogenesis. <i>Hepatology</i> , 2020, 72, 1864-1872.	3.6	221
25	Health related quality of life in chronic liver diseases. <i>Liver International</i> , 2020, 40, 2630-2642.	1.9	15
26	Surveillance for Hepatocellular Carcinoma in Patients with Non-Alcoholic Fatty Liver Disease: Universal or Selective?. <i>Cancers</i> , 2020, 12, 1422.	1.7	41
27	Liver Matrix in Benign and Malignant Biliary Tract Disease. <i>Seminars in Liver Disease</i> , 2020, 40, 282-297.	1.8	17
28	Cholangiocarcinoma 2020: the next horizon in mechanisms and management. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2020, 17, 557-588.	8.2	1,155
29	The Emerging Role of Macrophages in Chronic Cholangiopathies Featuring Biliary Fibrosis: An Attractive Therapeutic Target for Orphan Diseases. <i>Frontiers in Medicine</i> , 2020, 7, 115.	1.2	11
30	Animal models for cystic fibrosis liver disease (CFLD). <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2019, 1865, 965-969.	1.8	9
31	Molecular Pathogenesis: From Inflammation and Cholestasis to a Microenvironment-Driven Tumor. , 2019, , 167-182.		0
32	The challenges of primary biliary cholangitis: What is new and what needs to be done. <i>Journal of Autoimmunity</i> , 2019, 105, 102328.	3.0	86
33	Pathophysiology of Cystic Fibrosis Liver Disease: A Channelopathy Leading to Alterations in Innate Immunity and in Microbiota. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2019, 8, 197-207.	2.3	34
34	Fibrocystic Liver Disease. , 2019, , 201-218.		0
35	Pathobiology of inherited biliary diseases: a roadmap to understand acquired liver diseases. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2019, 16, 497-511.	8.2	73
36	Cholangiocyte pathobiology. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2019, 16, 269-281.	8.2	285

#	ARTICLE	IF	CITATIONS
37	The tumour microenvironment and immune milieu of cholangiocarcinoma. <i>Liver International</i> , 2019, 39, 63-78.	1.9	109
38	Modeling of implementation of the new Organ Procurement and Transplantation Network/United Network for Organ Sharing policy for patients with hepatocellular carcinoma. <i>Journal of Comparative Effectiveness Research</i> , 2019, 8, 993-1002.	0.6	1
39	Platelet-derived growth factor-D enables liver myofibroblasts to promote tumor lymphangiogenesis in cholangiocarcinoma. <i>Journal of Hepatology</i> , 2019, 70, 700-709.	1.8	112
40	Animal models of cholestasis: An update on inflammatory cholangiopathies. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2019, 1865, 954-964.	1.8	39
41	Liver diseases in the dish: iPSC and organoids as a new approach to modeling liver diseases. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2019, 1865, 920-928.	1.8	53
42	Intrahepatic Cholangiocarcinoma: Continuing Challenges and Translational Advances. <i>Hepatology</i> , 2019, 69, 1803-1815.	3.6	195
43	The deleterious interplay between tumor epithelia and stroma in cholangiocarcinoma. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2018, 1864, 1435-1443.	1.8	56
44	Pathophysiologic implications of innate immunity and autoinflammation in the biliary epithelium. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2018, 1864, 1374-1379.	1.8	41
45	Animal models of biliary injury and altered bile acid metabolism. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2018, 1864, 1254-1261.	1.8	105
46	Optimising the clinical strategy for autoimmune liver diseases: Principles of value-based medicine. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2018, 1864, 1415-1422.	1.8	3
47	Src kinase inhibition reduces inflammatory and cytoskeletal changes in Î²F508 human cholangiocytes and improves cystic fibrosis transmembrane conductance regulator correctors efficacy. <i>Hepatology</i> , 2018, 67, 972-988.	3.6	42
48	Î²-catenin and interleukin-1Î²-dependent chemokine (CXCL10) production drives progression of disease in a mouse model of congenital hepatic fibrosis. <i>Hepatology</i> , 2018, 67, 1903-1919.	3.6	38
49	Fibroinflammatory Liver Injuries as Preneoplastic Condition in Cholangiopathies. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3875.	1.8	21
50	Valproic Acid Inhibits Proliferation and Reduces Invasiveness in Glioma Stem Cells Through Wnt/Î²-Catenin Signalling Activation. <i>Genes</i> , 2018, 9, 522.	1.0	24
51	Animal models of cholangiocarcinoma: What they teach us about the human disease. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2018, 42, 403-415.	0.7	21
52	Molecular Mechanisms Driving Cholangiocarcinoma Invasiveness: An Overview. <i>Gene Expression</i> , 2018, 18, 31-50.	0.5	16
53	Dynamic contrast enhanced perfusion CT imaging: A diagnostic biomarker tool for survival prediction of tumour response to antiangiogenetic treatment in patients with advanced HCC lesions. <i>European Journal of Radiology</i> , 2018, 106, 62-68.	1.2	9
54	Value-based care in hepatology. <i>Hepatology</i> , 2017, 65, 1749-1755.	3.6	22

#	ARTICLE	IF	CITATIONS
55	Diagnostic value of dynamic contrast-enhanced CT with perfusion imaging in the quantitative assessment of tumor response to sorafenib in patients with advanced hepatocellular carcinoma: A feasibility study. <i>European Journal of Radiology</i> , 2017, 90, 34-41.	1.2	18
56	The Healthy Biliary Tree: Cellular and Immune Biology. , 2017, , 17-41.		1
57	Emerging concepts in biliary repair and fibrosis. <i>American Journal of Physiology - Renal Physiology</i> , 2017, 313, G102-G116.	1.6	63
58	ELITA consensus statements on the use of DAAs in liver transplant candidates and recipients. <i>Journal of Hepatology</i> , 2017, 67, 585-602.	1.8	71
59	Direct-acting antivirals combination for elderly patients with chronic hepatitis C: A cost-effectiveness analysis. <i>Liver International</i> , 2017, 37, 982-994.	1.9	19
60	Adenylyl cyclase 5 links changes in calcium homeostasis to cAMP-dependent cyst growth in polycystic liver disease. <i>Journal of Hepatology</i> , 2017, 66, 571-580.	1.8	31
61	Is the risk of neoplastic recurrence increased after prescribing direct-acting antivirals for HCV patients whose HCC was previously cured?. <i>Journal of Hepatology</i> , 2017, 66, 236-237.	1.8	80
62	Resveratrol Impairs Glioma Stem Cells Proliferation and Motility by Modulating the Wnt Signaling Pathway. <i>PLoS ONE</i> , 2017, 12, e0169854.	1.1	103
63	Autocrine and Paracrine Mechanisms Promoting Chemoresistance in Cholangiocarcinoma. <i>International Journal of Molecular Sciences</i> , 2017, 18, 149.	1.8	30
64	Notch signaling and progenitor/ductular reaction in steatohepatitis. <i>PLoS ONE</i> , 2017, 12, e0187384.	1.1	18
65	Tumor reactive stroma in cholangiocarcinoma: The fuel behind cancer aggressiveness. <i>World Journal of Hepatology</i> , 2017, 9, 455.	0.8	69
66	Revisiting Epithelial-to-Mesenchymal Transition in Liver Fibrosis: Clues for a Better Understanding of the "Reactive" Biliary Epithelial Phenotype. <i>Stem Cells International</i> , 2016, 2016, 1-10.	1.2	33
67	Macrophage recruitment by fibrocytin-defective biliary epithelial cells promotes portal fibrosis in congenital hepatic fibrosis. <i>Hepatology</i> , 2016, 63, 965-982.	3.6	80
68	Cystic Fibrosis-Related Liver Diseases: New Paradigm for Treatment Based on Pathophysiology. <i>Clinical Liver Disease</i> , 2016, 8, 113-116.	1.0	13
69	Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: A European study. <i>Journal of Hepatology</i> , 2016, 65, 524-531.	1.8	298
70	The cystic fibrosis transmembrane conductance regulator controls biliary epithelial inflammation and permeability by regulating Src tyrosine kinase activity. <i>Hepatology</i> , 2016, 64, 2118-2134.	3.6	55
71	Liver-allocation policies for patients affected by HCC in Europe. <i>Current Transplantation Reports</i> , 2016, 3, 313-318.	0.9	19
72	Effective but costly: How to tackle difficult trade-offs in evaluating health improving technologies in liver diseases. <i>Hepatology</i> , 2016, 64, 1331-1342.	3.6	10

#	ARTICLE	IF	CITATIONS
73	Low-Dose Paclitaxel Reduces S100A4 Nuclear Import to Inhibit Invasion and Hematogenous Metastasis of Cholangiocarcinoma. <i>Cancer Research</i> , 2016, 76, 4775-4784.	0.4	44
74	Stimulation of nuclear receptor peroxisome proliferator-activated receptor- β limits NF- κ B-dependent inflammation in mouse cystic fibrosis biliary epithelium. <i>Hepatology</i> , 2015, 62, 1551-1562.	3.6	106
75	Epithelial-to-Mesenchymal Transition and Cancer Invasiveness: What Can We Learn from Cholangiocarcinoma?. <i>Journal of Clinical Medicine</i> , 2015, 4, 2028-2041.	1.0	39
76	Emerging roles of Notch signaling in liver disease. <i>Hepatology</i> , 2015, 61, 382-392.	3.6	204
77	Leukemia inhibitory factor protects cholangiocarcinoma cells from drug-induced apoptosis via a PI3K/AKT-dependent Mcl-1 activation. <i>Oncotarget</i> , 2015, 6, 26052-26064.	0.8	51
78	Osteopontin: a new player in regulating hepatic ductular reaction and hepatic progenitor cell responses during chronic liver injury. <i>Gut</i> , 2014, 63, 1693-1694.	6.1	11
79	Notch signaling and new therapeutic options in liver disease. <i>Journal of Hepatology</i> , 2014, 60, 885-890.	1.8	94
80	Characterization of animal models for primary sclerosing cholangitis (PSC). <i>Journal of Hepatology</i> , 2014, 60, 1290-1303.	1.8	129
81	Neural cell adhesion molecule and polysialic acid in ductular reaction: The puzzle is far from completed, but the picture is becoming more clear. <i>Hepatology</i> , 2014, 60, 1469-1472.	3.6	9
82	Notch signalling beyond liver development: Emerging concepts in liver repair and oncogenesis. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2013, 37, 447-454.	0.7	61
83	Vascular biology of the biliary epithelium. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2013, 28, 26-32.	1.4	29
84	The balance between Notch/Wnt signaling regulates progenitor cells' commitment during liver repair: Mystery solved?. <i>Journal of Hepatology</i> , 2013, 58, 181-183.	1.8	15
85	Notch signaling regulates tubular morphogenesis during repair from biliary damage in mice. <i>Journal of Hepatology</i> , 2013, 59, 124-130.	1.8	78
86	Hepatitis B-core antibody positive donors in liver transplantation and their impact on graft survival: Evidence from the Liver Match cohort study. <i>Journal of Hepatology</i> , 2013, 58, 715-723.	1.8	44
87	Toward a rational management of very early hepatocellular carcinoma. <i>Hepatology</i> , 2013, 57, 1300-1302.	3.6	0
88	Isolation and characterization of biliary epithelial and stromal cells from resected human cholangiocarcinoma: A novel in vitro model to study tumor-stroma interactions. <i>Oncology Reports</i> , 2013, 30, 1143-1148.	1.2	33
89	Platelet-derived growth factor-D and Rho GTPases regulate recruitment of cancer-associated fibroblasts in cholangiocarcinoma. <i>Hepatology</i> , 2013, 58, 1042-1053.	3.6	139
90	Healthcare costs associated with hepatocellular carcinoma and the value of care. <i>Hepatology</i> , 2013, 58, 1213-1214.	3.6	7

#	ARTICLE	IF	CITATIONS
91	Protein kinase a-dependent pSer ⁶⁷⁵ - β -catenin, a novel signaling defect in a mouse model of congenital hepatic fibrosis. <i>Hepatology</i> , 2013, 58, 1713-1723.	3.6	43
92	Unveiling the role of tumor reactive stroma in cholangiocarcinoma: an opportunity for new therapeutic strategies. <i>Translational Gastrointestinal Cancer</i> , 2013, 2, 130-144.	3.0	27
93	Vascular endothelial growth factors in progenitor cells mediated liver repair. <i>Hepatobiliary Surgery and Nutrition</i> , 2013, 2, 65-7.	0.7	6
94	Development of the bile ducts: Essentials for the clinical hepatologist. <i>Journal of Hepatology</i> , 2012, 56, 1159-1170.	1.8	151
95	Cyclic AMP/PKA-dependent paradoxical activation of Raf/MEK/ERK signaling in polycystin-2 defective mice treated with sorafenib. <i>Hepatology</i> , 2012, 56, 2363-2374.	3.6	56
96	Notch Signaling in Hepatocellular Carcinoma: Guilty in Association!. <i>Gastroenterology</i> , 2012, 143, 1430-1434.	0.6	48
97	Altered store operated calcium entry increases cyclic 3',5'-adenosine monophosphate production and extracellular signal-regulated kinases 1 and 2 phosphorylation in polycystin-2-defective cholangiocytes: [RETRACTED]. <i>Hepatology</i> , 2012, 55, 856-868.	3.6	56
98	Loss of CFTR Affects Biliary Epithelium Innate Immunity and Causes TLR4/NF- κ B Mediated Inflammatory Response in Mice. <i>Gastroenterology</i> , 2011, 141, 1498-1508.e5.	0.6	114
99	Systemic Therapy in Hepatocellular Carcinoma. <i>Clinics in Liver Disease</i> , 2011, 15, 423-441.	1.0	26
100	Polycystic Liver Diseases: Congenital Disorders of Cholangiocyte Signaling. <i>Gastroenterology</i> , 2011, 140, 1855-1859.e1.	0.6	70
101	Cholangiocarcinoma in Italy: A national survey on clinical characteristics, diagnostic modalities and treatment. Results from the "Cholangiocarcinoma" committee of the Italian Association for the Study of Liver disease. <i>Digestive and Liver Disease</i> , 2011, 43, 60-65.	0.4	59
102	Liver Match, a prospective observational cohort study on liver transplantation in Italy: Study design and current practice of donor-recipient matching. <i>Digestive and Liver Disease</i> , 2011, 43, 155-164.	0.4	69
103	"The city of Hepar": Rituals, gastronomy, and politics at the origins of the modern names for the liver. <i>Journal of Hepatology</i> , 2011, 55, 1132-1136.	1.8	36
104	Nuclear expression of S100A4 calcium-binding protein increases cholangiocarcinoma invasiveness and metastasization. <i>Hepatology</i> , 2011, 54, 890-899.	3.6	82
105	Dual farnesoid X receptor/TGR5 agonist INT-767 reduces liver injury in the <i>Mdr2</i> (<i>Abcb4</i>) mouse cholangiopathy model by promoting biliary HCO ₃ output. <i>Hepatology</i> , 2011, 54, 1303-1312.	3.6	193
106	Epithelial-Mesenchymal Interactions in Biliary Diseases. <i>Seminars in Liver Disease</i> , 2011, 31, 011-032.	1.8	76
107	Insulin resistance and necroinflammation drives ductular reaction and epithelial-mesenchymal transition in chronic hepatitis C. <i>Gut</i> , 2011, 60, 108-115.	6.1	30
108	Mammalian target of rapamycin regulates vascular endothelial growth factor-dependent liver cyst growth in polycystin-2-defective mice. <i>Hepatology</i> , 2010, 51, 1778-1788.	3.6	87

#	ARTICLE	IF	CITATIONS
109	Prediction of progression-free survival in patients presenting with hepatocellular carcinoma within the Milan criteria. <i>Liver Transplantation</i> , 2010, 16, 503-512.	1.3	41
110	ERK1/2-Dependent Vascular Endothelial Growth Factor Signaling Sustains Cyst Growth in Polycystin-2 Defective Mice. <i>Gastroenterology</i> , 2010, 138, 360-371.e7.	0.6	90
111	Genetic associations in Italian primary sclerosing cholangitis: Heterogeneity across Europe defines a critical role for HLA-C. <i>Journal of Hepatology</i> , 2010, 52, 712-717.	1.8	50
112	Foxa1 and Foxa2 regulate bile duct development in mice. <i>Journal of Hepatology</i> , 2010, 52, 765-767.	1.8	14
113	Cholangiocyte Biology as Relevant to Cystic Liver Diseases. , 2010, , 23-43.		3
114	Side chain structure determines unique physiologic and therapeutic properties of norursodeoxycholic acid in Mdr2 ^{-/-} mice. <i>Hepatology</i> , 2009, 49, 1972-1981.	3.6	135
115	Diferentially expressed adenylyl cyclase isoforms mediate secretory functions in cholangiocyte subpopulation. <i>Hepatology</i> , 2009, 50, 244-252.	3.6	52
116	Epithelial expression of angiogenic growth factors modulate arterial vasculogenesis in human liver development. <i>Hepatology</i> , 2008, 47, 719-728.	3.6	60
117	Functional Anatomy of Normal Bile Ducts. <i>Anatomical Record</i> , 2008, 291, 653-660.	0.8	105
118	Incidence and Management of Colorectal Cancer in Liver Transplant Recipients. <i>Clinical Colorectal Cancer</i> , 2008, 7, 260-266.	1.0	23
119	Morphological and Functional Features of Hepatic Cyst Epithelium in Autosomal Dominant Polycystic Kidney Disease. <i>American Journal of Pathology</i> , 2008, 172, 321-332.	1.9	79
120	Treatment With Pegylated Interferon and Ribavirin for Hepatitis C Virus-associated Severe Cryoglobulinemia in a Liver/Kidney Transplant Recipient. <i>Journal of Clinical Gastroenterology</i> , 2007, 41, 216-220.	1.1	36
121	Analysis of Liver Repair Mechanisms in Alagille Syndrome and Biliary Atresia Reveals a Role for Notch Signaling. <i>American Journal of Pathology</i> , 2007, 171, 641-653.	1.9	120
122	Ursodeoxycholic Acid Stimulates Cholangiocyte Fluid Secretion in Mice via CFTR-Dependent ATP Secretion. <i>Gastroenterology</i> , 2007, 133, 1603-1613.	0.6	104
123	A randomized study on Peg-interferon alfa-2a with or without ribavirin in liver transplant recipients with recurrent hepatitis C. <i>Journal of Hepatology</i> , 2007, 46, 1009-1017.	1.8	96
124	Extended right split liver graft for primary transplantation in children and adults*. <i>Transplant International</i> , 2006, 19, 492-499.	0.8	56
125	Liver transplant in cystic fibrosis: a poll among European centers. A study from the European Liver Transplant Registry. <i>Transplant International</i> , 2006, 19, 726-731.	0.8	62
126	Effects of angiogenic factor overexpression by human and rodent cholangiocytes in polycystic liver diseases. <i>Hepatology</i> , 2006, 43, 1001-1012.	3.6	138

#	ARTICLE	IF	CITATIONS
127	Pathophysiology of Cholangiopathies. <i>Journal of Clinical Gastroenterology</i> , 2005, 39, S90-S102.	1.1	152
128	Glibenclamide Stimulates Fluid Secretion in Rodent Cholangiocytes Through a Cystic Fibrosis Transmembrane Conductance Regulator-Independent Mechanism. <i>Gastroenterology</i> , 2005, 129, 220-233.	0.6	24
129	Difficulty with diagnosis of malignant pancreatic neoplasms coexisting with chronic pancreatitis. <i>World Journal of Gastroenterology</i> , 2005, 11, 5075.	1.4	52
130	The cholangiopathies: Disorders of biliary epithelia. <i>Gastroenterology</i> , 2004, 127, 1565-1577.	0.6	326
131	Cytokine-stimulated nitric oxide production inhibits adenylyl cyclase and cAMP-dependent secretion in cholangiocytes. <i>Gastroenterology</i> , 2003, 124, 737-753.	0.6	129
132	Correction of CFTR malfunction and stimulation of Ca ²⁺ -activated Cl ⁻ channels restore HCO ₃ ⁻ secretion in cystic fibrosis bile ductular cells. <i>Hepatology</i> , 2002, 35, 95-104.	3.6	50
133	Defective regulation of cholangiocyte Cl ⁻ /HCO ₃ ⁻ and Na ⁺ /H ⁺ exchanger activities in primary biliary cirrhosis. <i>Hepatology</i> , 2002, 35, 1513-1521.	3.6	95
134	Proinflammatory Cytokines Inhibit Secretion in Rat Bile Duct Epithelium. <i>Gastroenterology</i> , 2001, 121, 156-169.	0.6	119
135	Ductular morphogenesis and functional polarization of normal human biliary epithelial cells in three-dimensional culture. <i>Journal of Hepatology</i> , 2001, 35, 2-9.	1.8	34
136	Pathophysiology of the intrahepatic biliary epithelium. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2000, 15, 244-253.	1.4	77
137	Ca ²⁺ -activated Cl ⁻ channels can substitute for CFTR in stimulation of pancreatic duct bicarbonate secretion. <i>FASEB Journal</i> , 2000, 14, 2345-2356.	0.2	55
138	Characterization and Isolation of Ductular Cells Coexpressing Neural Cell Adhesion Molecule and Bcl-2 from Primary Cholangiopathies and Ductal Plate Malformations. <i>American Journal of Pathology</i> , 2000, 156, 1599-1612.	1.9	121
139	Purinergic regulation of acid/base transport in human and rat biliary epithelial cell lines. <i>Hepatology</i> , 1998, 28, 914-920.	3.6	48
140	Liver and Biliary Problems in Cystic Fibrosis. <i>Seminars in Liver Disease</i> , 1998, 18, 227-235.	1.8	111
141	Functional polarity of Na ⁺ /H ⁺ and Cl ⁻ /HCO ₃ ⁻ exchangers in a rat cholangiocyte cell line. <i>American Journal of Physiology - Renal Physiology</i> , 1998, 275, G1236-G1245.	1.6	30
142	Epstein-Barr virus-associated post-transplant lympho-proliferative disease of donor origin in liver transplant recipients. <i>Journal of Hepatology</i> , 1997, 26, 926-934.	1.8	45
143	New insights into cholangiocyte physiology. <i>Journal of Hepatology</i> , 1997, 27, 945-952.	1.8	49
144	Regulation of intracellular pH in the hepatocyte. <i>Journal of Hepatology</i> , 1996, 24, 631-644.	1.8	37

#	ARTICLE	IF	CITATIONS
145	The Effect of Drugs on Bile Flow and Composition. <i>Drugs</i> , 1986, 31, 430-448.	4.9	34
146	Unmet needs in basic and translational research in Cholangiocarcinoma. <i>Liver Cancer International</i> , 0, , .	0.2	0